The estimated Net Worth of Donald H Picker is at least $459 millier dollars as of 22 June 2024. Dr Picker owns over 1,766 units of Moleculin Biotech Inc stock worth over $20,460 and over the last 7 years he sold MBRX stock worth over $0. In addition, he makes $438,156 as Chief Scientific Officer at Moleculin Biotech Inc.
Sign up
Dr D MBRX stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Moleculin Biotech Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 1,766 units of MBRX stock worth $4,238 on 22 June 2024.
The largest trade he's ever made was exercising 16,167 units of Moleculin Biotech Inc stock on 16 June 2023 worth over $38,801. On average, Dr trades about 1,901 units every 37 days since 2017. As of 22 June 2024 he still owns at least 8,525 units of Moleculin Biotech Inc stock.
You can see the complete history of Dr Picker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Donald H. Picker Ph.D. biography
Dr. Donald H. Picker Ph.D. is the Chief Scientific Officer at Moleculin Biotech Inc.
What is the salary of Dr D?
As the Chief Scientific Officer of Moleculin Biotech Inc, the total compensation of Dr D at Moleculin Biotech Inc is $438,156. There are 3 executives at Moleculin Biotech Inc getting paid more, with Walter V. Klemp having the highest compensation of $778,144.
How old is Dr D?
Dr D is 75, he's been the Chief Scientific Officer of Moleculin Biotech Inc since . There are no older and 10 younger executives at Moleculin Biotech Inc.
What's Dr D's mailing address?
Donald's mailing address filed with the SEC is C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON, TX, 77007.
Insiders trading at Moleculin Biotech Inc
Over the last 8 years, insiders at Moleculin Biotech Inc have traded over $340,000 worth of Moleculin Biotech Inc stock and bought 433,338 units worth $371,310 . The most active insiders traders include Walter V Klemp, John M Climaco et Waldemar Priebe. On average, Moleculin Biotech Inc executives and independent directors trade stock every 75 days with the average trade being worth of $69,293. The most recent stock trade was executed by Walter V Klemp on 2 July 2024, trading 982 units of MBRX stock currently worth $2,357.
What does Moleculin Biotech Inc do?
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.
What does Moleculin Biotech Inc's logo look like?
Complete history of Dr Picker stock trades at Moleculin Biotech Inc
Moleculin Biotech Inc executives and stock owners
Moleculin Biotech Inc executives and other stock owners filed with the SEC include:
-
Walter V. Klemp,
Founder, Chairman, Pres & CEO -
Jonathan P. Foster CPA,
Exec. VP & CFO -
Jonathan P. Foster,
Exec. VP & CFO -
Dr. Donald H. Picker Ph.D.,
Chief Scientific Officer -
Dr. Donald H. Picker,
Chief Scientific Officer -
Dr. Sandra L. Silberman M.D., Ph.D.,
Chief Medical Officer of New Products -
Dr. John Paul Waymack M.D., Sc.D.,
Sr. Chief Medical Officer -
Louis Ploth Jr.,
Independent Advisor -
Jacqueline Northcut,
Consultant -
Dr. Sandra L. Silberman,
Chief Medical Officer of New Products -
Dr. Robert C. Shepard FACP, M.D., F.A.C.P.,
Chief Medical Officer of Annamycin -
Dr. Waldemar Priebe Ph.D.,
Co-Founder & Chairman of Scientific Advisory Board -
Jacqueline Northcut,
Director -
Michael D Cannon,
Director -
Robert E. George,
Director -
John M Climaco,
Director -
Waldemar Priebe,
10% owner -
Donald H Picker,
Chief Science Officer -
Walter V Klemp,
CEO and President -
Elizabeth Cermak,
Director -
Joy Yan,
Director -
Jonathan P. Foster,
Chief Financial Officer